TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

488

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

September 20, 2024

Study Completion Date

February 28, 2025

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

TAB014 Monoclonal Antibody Injection

intravitreal injection at 1.25mg once every 4 weeks

DRUG

Ranibizumab Injection [Lucentis]

intravitreal injection at 0.5mg once every 4 weeks

Trial Locations (56)

100021

Beijing Aier Intech Eye Hospital, Beijing

100044

Peking University People'S Hospital, Beijing

100191

Peking University Third Hospital, Beijing

100730

Beijing Hospital, Beijing

Beijing Tongren Hospital, Cmu, Beijing

Peking Union Medical College Hospital, Beijing

110000

The Fourth People's Hospital of Shenyang, Shenyang

110034

Shenyang He Eye Hospital, Shenyang

116091

Dalian No.3 People'S Hospital, Dalian

130021

The First Hospital of Jilin University, Jilin

150001

The First Affiliated Hospital of Harbin Medical University, Harbin

200041

Shanghai Eye Disease Prevention and Treatment Center, Shanghai

200072

Shanghai Tenth People's Hospital(Tenth People's Hospital of Tongji Unversity), Shanghai

200080

Shanghai General Hospital, Shanghai

214002

Wuxi No.2 People's Hospital, Wuxi

230601

The Second Hospital of Anhui Medical University, Hefei

261041

Weifang Eye Hospital Co., Ltd., Weifang

300020

Tianjin Eye Hospital, Tianjin

300384

Tianjin Medical University Eye Hospital, Tianjin

310003

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), Hangzhou

310014

Zhejiang Provincial People'S Hospital, Hangzhou

325027

Eye Hospital, WMU, Wenzhou

330006

Affiliated Eye Hospital of Nanchang University, Nanchang

330008

The Second Affiliated Hospital of Nanchang University, Nanchang

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

400016

The First Affiliated Hospital of Chongqing Medical University, Chongqing

410005

Hunan Provincial People's Hospital, Changsha

410008

Xiangya Hospital of Central South University, Changsha

410015

Aier Eye Hospital(Changsha), Changsha

430030

Tongji Hospital® Tongji Medical Collehe of Hust, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

430070

Central theater General Hospital, Wuhan

430081

Wuhan Puren Hospital, Wuhan

442000

Taihe Hospital (Affiliated Hospital of Hubei University of Medicine), Shiyan

450008

Henan Eye Hospital& Henan Eye Institute, Zhengzhou

450015

Zhengzhou Second Hospital, Zhengzhou

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

475000

Kaifeng Central Hopital, Kaifeng

510080

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

510180

Guangzhou First People's Hospital, Guangzhou

510260

The Second Affiliated Hospital of Guangzhou Medical, Guangzhou

510623

Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou

515041

Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou

518031

Shenzhen Aier Eye Hospital, Shenzhen

550004

The Affiliated Hospital of Guizhou Medical University, Guiyang

563000

Affiliated Hospital of Zunyi Medical University, Zunyi

610041

Chengdu Aier Eye Hospital, Chengdu

West China Hospital of Sichuan University, Chengdu

610084

Ineye Hospital of Chengdu University of TCM, Chengdu

710002

Xi'an No.1 Hospital, Xi’an

710004

Xi'An Fourth Hospital, Xi’an

061017

Cangzhou Central Hospital, Cangzhou

054001

Hebei Eye Hospital, Xingtai

046000

Changzhi People'S Hospital, Changzhi

030699

The First People's Hospital of Jinzhong(Jinzhong Hospital Affiliated to Shanxi Medical University), Jinzhong

030002

Shanxi Eye Hospital, Taiyuan

All Listed Sponsors
collaborator

Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

INDUSTRY

lead

BioDlink Biopharm Co., Ltd.

INDUSTRY